The Sale of Astra Tech Implant Is a Smart Move

Dentsply is to acquire AstraZeneca's Astra Tech implant unit for $1.8billion and we believe this is a positive development for both firms

Bill Buhr 23 June, 2011 | 12:28PM
Facebook Twitter LinkedIn

Dentsply (XRAY) announced this Wednesday it plans to acquire AstraZeneca's (AZN) Astra Tech implant unit for roughly $1.8 billion. We think this is a smart move for both firms, as it provides Dentsply an avenue to increase its presence in the high-growth, high-margin implant segment and allows AstraZeneca to shed a noncore business unit. We have no plans to adjust our fair value estimate for Dentsply at this time.

Morningstar Equity Analysis is available to Premium members. Read our analyst's fair value estimate and investment thesis by clicking here. Subscribe to Premium here.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC12,024.00 GBX-1.09Rating

About Author

Bill Buhr  Bill Buhr is an IPO strategist and stock analyst with Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures